[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644748":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":20,"locations":21,"responsibleParty":41,"collaborators":20,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":20,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":20,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":68,"whyStopped":20,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Radiotherapy","EXPERIMENTAL","Radical dose is delivered for the patients. . SFRT is recommended for the patients with bulky tumor (such as ≥ 5cm). SFRT is delivered with 12-20Gy (1 fraction) followed by EBRT with EQD2≥60Gy.",[13],"Radiation: Radical dose radiotherapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","Radical dose radiotherapy","Radical dose is delivered for the patients. SFRT is recommended for the patients with bulky tumor (such as ≥ 5cm). SFRT is delivered with 12-20Gy (1 fraction) followed by external beam radiation therapy (EBRT) with EQD2≥60Gy.",[9],null,[22],{"facility":23,"status":20,"city":24,"state":25,"zip":26,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"Cancer Hospital, Chinese Academy of Medical Sciences","Beijing","Beijing Municipality","100021","China","CN",{"type":30,"coordinates":31},"Point",[32,33],116.39723,39.9075,{"lat":33,"lon":32},[36],{"name":37,"role":38,"phone":39,"phoneExt":20,"email":40},"Shu-Lian Wang, MD.","CONTACT","+86-010-87787659","wangsl@cicams.ac.cn",{"type":42,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Shulian Wang,MD","Chief Physician","100644748","a-phase-ii-study-of-radiation-therapy-to-treat-refractory-breast-cancer-100644748",false,"NCT07672743","A Phase II Study of Radiation Therapy to Treat Refractory Breast Cancer","A Prospective Phase II Study of Radiation Therapy to Treat Refractory Breast Cancer","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;\n* Locally advanced or recurrent metastatic breast cancer, pathologically confirmed;\n* At least one extracranial measurable lesion suitable for radiotherapy;\n* Signature of informed consent form.\n\nExclusion Criteria:\n\n* Pregnant or lactation women;\n* Severe concomitant conditions, including persistent or active infections, symptomatic congestive heart failure, unstable angina pectoris, and serious arrhythmias et al.","FEMALE","18 Years","75 Years",{"count":56,"type":57},29,"ESTIMATED","INTERVENTIONAL",[60],"NA","For locally advanced or recurrent metastatic breast cancer that is resistant to systemic therapy, radiotherapy (RT) may be considered as the preferred treatment option when the lesion is unresectable, or the patient is not suitable for surgery. This study aim to evelatuate the local control of radical dose RT or new RT technique (such as patially fractionated radiation therapy, SFRT) for the locally advanced or recurrent metastatic breast cancer.",[63],"Breast Cancer",[65,66,67],"breast cancer","radiotherapy","spatially fractionated radiation therapy","NOT_YET_RECRUITING","2026-06-22",{"date":71,"type":72},"2026-06-29","ACTUAL",{"date":74,"type":57},"2026-06-30",{"date":76,"type":57},"2027-12-31",{"name":5,"class":6},1]